Jeremy Cole, MD
Sleep Medicine · Edmond, OKNPI 1962586701
Payments from drug & device makers
Across 1,875 payments — averaging $8715.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$5M
- AstraZeneca$3.9M
- Genentech, Inc.$1.9M
- AbbVie$892K
- Teva Pharmaceuticals USA, Inc.$885K
- Astrazeneca UK Limited$873K
- plus $2.8M from 18 others
Across 16 payments — averaging $3402.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$49K
- Sanofi$5K
What the payments were for
- Consulting fees$1,32026%
- Speaking & faculty fees$1,25025%
- Travel & lodging$99620%
- Food & beverage$97019%
- Education$53010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 556 | $5,038,214 |
| AstraZeneca | 57 | $3,923,397 |
| Genentech, Inc. | 271 | $1,894,487 |
| AbbVie(2 entities) | 92 | $892,153 |
| Teva Pharmaceuticals USA, Inc. | 192 | $885,443 |
| Astrazeneca UK Limited | 15 | $873,305 |
| Chiesi USA, Inc. | 315 | $774,862 |
| Biohaven Pharmaceuticals, Inc. | 41 | $369,614 |
| Cipla USA Inc. | 216 | $344,027 |
| Hikma Pharmaceuticals USA | 8 | $320,575 |
| Sanofi | 29 | $319,866 |
| Pfizer | 20 | $256,736 |
| Biohaven Pharmaceutical Holding Company Ltd. | 19 | $205,830 |
| Astrazeneca AB | 4 | $146,692 |
| Amgen | 3 | $81,768 |
| Avanir Pharmaceuticals, Inc. | 1 | $13,557 |
| Currax Pharmaceuticals LLC | 1 | $1,000 |
| Jazz Pharmaceuticals Inc. | 13 | $631 |
| GSK | 8 | $119 |
| Inogen, Inc. | 9 | $83 |
| Harmony Biosciences LLC | 2 | $37 |
| Itamar Medical Inc | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,342,469 in reported general payments places this provider in the 95th percentile of 20 sleep medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 13 | $220,454 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $63,675 |
| JardianceEmpagliflozin | 33 | $32,978 |
| OzempicSemaglutide | 23 | $30,552 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $16,616 |
| EliquisApixaban | 13 | $8,883 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,648 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 22 | $4,606 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 14 | $4,024 |
| Modafinil | 25 | $2,250 |
| Gabapentin | 87 | $1,638 |
| Rosuvastatin Calcium | 71 | $1,591 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,434 |
| Montelukast Sodium | 74 | $1,350 |
| Omeprazole | 88 | $1,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Shingrix, Arexvy | $119 | $72,305123 claims |
| AstraZenecaBreztri Aerosphere | $3,923,397 | $16,61618 claims |
| PfizerEliquis | $256,736 | $8,88313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 sleep medicine providers in Oklahoma.
Other sleep medicine in Edmond
- Michael NewnamTulsa$284K
- Viral DoshiOklahoma City$56K
- Asim MaqsoodOklahoma City$7K
- Marilyn CulpTulsa$4K
- Cory CrossOklahoma City$3K
- Amritanshu SinghTulsa$3K
- Keziah AibangbeeTulsa$2K
- Richard BregmanTulsa$2K
- Jeffrey JonesDuncan$1K
- Jared ColvertOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.